Kornimate/medical-research-clean huggingface dataset:
asthma breath biomarker assessment

Conditions: Asthma Acute

Summary: this study aims to assess the feasibility of capturing data on exhaled breath compounds during an acute asthma exacerbation. in addition to assessing the feasibility of such a study the investigators will collect data on exploratory outcomes including the ability of breath biomarkers to distinguish between controlled and exacerbated states and their ability to differentiate between triggers of exacerbation.

this will be a longitudinal observational study in which the investigators assess the ability to capture information on volatile organic compounds in exhaled breath during an acute asthma exacerbation using two different approaches: a) recruitment and assessment of patients in secondary care during an acute exacerbation of their asthma; patients to be re-assessed once their asthma is stable and controlled. b) recruitment of clinically stable outpatients who are at increased risk of exacerbation by virtue of having had an acute exacerbation within the previous 12 months. participants to be followed for a period of up to 12 months; assessed in the event of an exacerbation; and re-assessed once controlled.

Eligibility criteria:
inclusion criteria: 1. male or female 2. aged 18 or above 3. able to provide informed consent 4. a confirmed asthma diagnosis requiring treatment with inhaled bronchodilator therapy +/- inhaled corticosteroids. 5. non-smoker (or ex-smoker of 6 months or more with a less than 10 pack year history). 6. current exacerbation or exacerbation within the previous 12 months. 7. within 24 hours of having presented to acute secondary care (applicable to current exacerbation only) exclusion criteria: 1. major chronic cardiorespiratory disease other than asthma 2. significant comorbid condition 3. receiving maintenance oral corticosteroid therapy or other immunosuppressant or immunomodulatory therapy (including biologics) 4. pregnant 5. participating in a clinical trial of an investigational medicinal product (ctimp). 6. unable to speak english.
profiling urticaria for the identification of subtypes

Conditions: Non-autoreactive Chronic Spontaneous Urticaria; Autoimmune Chronic Spontaneous Urticaria; Autoreactive, Non-autoimmune Chronic Spontaneous Urticaria

Summary: the primary purpose of this study is to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria. additional aims: include the comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria.


Eligibility criteria:
inclusion criteria: * chronic spontaneous urticaria * disease duration \> 6 weeks * signed and dated informed consent * age 18 years or older * non sedating antihistamines may be used on an "on demand" basis throughout the study, in case of high urticaria activity \[\>50 wheals, and intense pruritus: urticaria activity score (uas) of 6\] or in case of an emergency. patients may take either cetirizine 10 mg up to a maximum of 4 tablets per 24 hours or fexofenadine 180 mg up to a maximum of 4 tablets per 24 hours. the use of antihistamines and the reason has to be documented by the patient in the patient diary. patients should avoid the use of antihistamines during the study and especially during the three days prior to skin testing * for female with childbearing potential: female will have to use a safe method of contraception to prevent pregnancy and will have to agree to continue this method of contraception during the whole study. exclusion criteria: * intake of immunosuppressives 3 month before screening visit and during the course of the study. immunosuppressives including ciclosporin, methotrexate, mycophenolate, azathioprine and cyclophosphamide need to be stopped at least 3 month before screening visit * intake of corticosteroids (e.g. oral, injection) 1 month before screening visit and during the course of the study. corticosteroids need to be stopped at least 1 month before the screening visit. * previous or present treatment with anti-ige-antibodies including omalizumab (xolair) * age below 18 years * use of tricyclic antidepressants (e.g. amitriptyline), doxepin, leukotriene antagonists (e.g. montelukast, trade name: singulair), h2 antihistamines (e.g. cimetidine, famotidine, ranitidine), sulphasalazine, dapsone, tranexamic acid, warfarin, heparin during the last 4 weeks before the screening visit and during the course of the study. * pregnancy, lactation or planned pregnancy during the study * mentally incapacitated subjects * patients protected by the law (adults under guardianship, or hospitalized in a public or private institution for a reason other than the study, or incarcerated) * patients suffering from urticaria vasculitis
gut and vaginal microbiota profile study for hiv women

Conditions: HPV; HIV Infections; Vaginal Microbiota

Summary: women living with hiv infection （wlhiv）are intended to acquire hpv infection which usually contributes to variable cervical lesions. we hypothesize that vaginal microbiota imbalance may make wlhiv prone to hpv infection，thereafter results in severe cervical lesion.

women living with hiv infection （wlhiv）are intended to acquire hpv infection which usually contributes to variable cervical lesions. besides the hpv co-infection, microbiota study recently reveals that the changes of vaginal bacteria spectrum might also be related with cervical disease in wlhiv. however, data on hpv prevalence in wlhiv and its associated cervical lesion incidence is still limited in china. moreover, the causal relationship between vaginal microbiota and cervical lesion in wlhiv is not clear. here, we hypothesize that vaginal microbiota imbalance may make wlhiv prone to hpv infection，thereafter results in severe cervical lesion.

Eligibility criteria:
inclusion criteria: * hiv women （including pregnant）; * sign consent paper exclusion criteria: * virgin or maiden

Keywords: hpv women with hpv infection vaginal microbiota gut microbiota
effects of dry needling and strain counter strain technique in myofascial trigger points of upper trapezius

Conditions: Trigger Point Pain, Myofascial

Summary: to determine the effects of dry needling and strain counter strain technique in myofascial trigger points of upper trapezius

it is randomized controlled trail will be conduct in mayo hospital lahore and alnoor hospital awan town lahore. non probability consecutive sampling technique will be used to collect the data. each group contain the 14 patients, patient will be divided into two groups. group a will be experimental group treated by dry needling and strain counter strain with baseline treatment and group b will be control group treated by strain counter strain with baseline treatment(hot pack 10 mints,stretching,neck isometrics). neck disability index (ndi) ,visual analogue scale(vas) and goniometer will be used as data collecting tools.

Eligibility criteria:
inclusion criteria: * patients with non-specific neck pain, having active myofascial trigger points in upper trapezius muscle. * patient of both gender under the age of 20-40 year * bilateral pain involving the upper trapezius * a duration of pain of at least 3 months * pain localized in the cervical and occipital regions but not in the orofacial region. * restricted cervical range of motion(side flexion) exclusion criteria: * history of traumatic injuries (e.g., contusion, fracture, and whiplash injury) * needle phobia patients. * systemic diseases such as blood coagula tion disorders, chronic pain syndrome, cancer,allergies fibromyalgia, systemic lupus erythematous, and psoriatic arthritis. * cervical spine surgery patients. * orofacial pain and temporomandibular disorders * neurologic disorders (e.g., trigeminal neuralgia or occipital neuralgia) * medical diagnosis of any primary headache (tension type or migraine) clinical diagnosis of cervical radiculopathy or myelopathy * history of previous physical therapy intervention for the cervical region in last 6 month * use of anticoagulants, opioids or antiepileptic medications

Keywords: dry needling myofascial trigger points upper trapezius strain counter strain
korean multicenter registry of innova stent for femoropopliteal artery disease: (k-innova registry)

Conditions: Femoropopliteal Artery Disease

Summary: * prospective, single-arm, multi-center registry study * a total of 150 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included. * patients will be followed clinically for 12 months after the procedure. * duplex ultrasound, ct or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months. * presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months. * quality of life by standardized questionnaires (at baseline \& at 1 \& 12 months)


Eligibility criteria:
inclusion criteria: 1. age 19 years of older 2. symptomatic peripheral artery disease: * moderate or severe claudication (rutherford category 2 or 3) * critical limb ischemia (rutherford category 4-5) 3. femoropopliteal artery lesions with stenosis \> 50% 4. abi \< 0.9 5. patients with signed informed consent exclusion criteria: 1. acute critical limb ischemia 2. severe critical limb ischemia (rutherford category 6) 3. known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents 4. in-stent restenosis lesions (restenosis lesions without previously implanted stents are eligible to the enrollment) 5. bypass graft lesions 6. age \> 85 years 7. severe hepatic dysfunction (\> 3 times normal reference values) 8. significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis 9. lvef \< 40% or clinically overt congestive heart failure 10. pregnant women or women with potential childbearing 11. life expectancy \<1 year due to comorbidity 12. untreated proximal inflow disease of the ipsilateral iliac arteries (more than 50% stenosis or occlusion)

Keywords: peripheral artery disease femoropopliteal artery nitinol stent restenosis
effects of perioperative intravenous dexamethasone on pain in out patient knee surgery

Conditions: Post Operative Pain; Nausea

Summary: the purpose of the study is to determine the opiate sparing effects of intravenously administered dexamethasone in outpatient knee surgery. dexamethasone is a glucocorticoid with well known antiemetic effects. however, the analgesic effects of dexamethasone have not been adequately researched. following surgery, patients are typically discharged home with po opiates to manage post-operative pain. the investigators believe that by using vas (visual analog scale) for pain the investigators can show that a single dose of dexamethasone can reduce pain scales and opiate consumption post-operatively, on post operative day (pod 1) when compared to placebo.

findings of modest improvement in pain scores and postoperative nausea at 24 hours with dexamethasone

Eligibility criteria:
inclusion criteria: * adult patients undergoing ambulatory knee arthroscopy surgery * must provide phone contact number and agree to phone followup on post operative day 1 exclusion criteria: * patients with major systemic disease * allergy or intolerance to study drug
longitudinal registry for advanced heart failure patients

Conditions: Heart Failure, Congestive; Heart Decompensation

Summary: the purpose of this study is to gather information to better understand the characteristics, medical management techniques and outcomes of patients with chronic severe heart failure (hf).

this objectives of this observational registry are: to assess changes in patient quality of life as a function of medical management and disease progression as measured by the rate of death and rehospitalization, and assist with the optimization of heart failure (hf) management by providing information on the use of therapies proven to be effective and to describe practices of standard of care for chronic treatment of symptoms of hf outside the hospital and during hospitalization for acute episode with intravenous vasoactive medication (drugs which affect the blood vessels and muscle of the heart). additional information which will be gathered include patient characteristics (age, sex, race, medical history, symptoms), infusion setting, type of medication, dose and frequency of medication and worsening of congestive heart failure disease. participants in the study receive an unique patient-specific identifier and all available data will be analyzed. observational study - no investigational drug administered

Eligibility criteria:
inclusion criteria: * age older than or equal to 18 years at the time of entry into the registry * severe symptoms of hf at rest with marked limitation of physical activity continuously for at least 60 days prior to inclusion in the registry * patient has been hospitalized 2 times in the past 12 months with a primary diagnosis of hf * patient's hf is refractory or relatively refractory to usual non-iv medications, as defined by having received one of the two following regimens for the treatment of hf in that last 60 days: 2 complete iv infusions, each lasting at least 2 hours, of either vasoactive (drugs having an effect on veins or arteries) or inotrope medications (drugs that makes the heart works better), or 3 iv diuretic (drugs that increase the elimination of urine) treatments exclusion criteria: * history of any organ transplantation * patient is expected to die within the next 5 days * patient is seen for consultation or evaluation only, and is unlikely to receive follow-up care at the participating clinic/hospital * participation in a clinical study of the drug natrecor

Keywords: heart failure, congestive heart decompensation
infrahepatic inferior vena cava clamping versus selective hepatic vascular exclusion involving the portal triad clamping

Conditions: Liver Neoplasms; Liver Cirrhosis

Summary: this clinical trial aims to compare infrahepatic inferior vena cava clamping (iivcc) with selective hepatic vascular exclusion (shve) involving the portal triad clamping (ptc) in complex cirrhotic liver resection. one group will receive iivcc plus ptc, while an another equivalent group patients will be operated using shve and ptc.

intraoperative blood loss is significantly associated with clinical outcomes of patients undergoing hepatectomy. there have been various hepatic vascular control techniques, including infrahepatic inferior vena cava clamping (iivcc) and selective hepatic vascular exclusion (shve).the propose of this study is to compare these two surgical techniques combined with the portal triad clamping (ptc) in hepatic cirrhotic patients. all patients being performed hepatectomy at the center are scanned according to inclusion and exclusion criteria. after intraoperative exploration, patients are randomized into two interventional groups. ptc, iivcc or shve is performed at the specified timepoint in liver parenchymal transection in two different groups. all data are collected prospectively.

Eligibility criteria:
inclusion criteria: 1. either male or female, older than 18 (include 18). 2. tumors oppress or be in close proximity to one or more of major hepatic veins. 3. the maximum diameter of tumor ≥ 5cm, number of lesions ≤ 3 and should be in same liver lobe if multiple lesions exit. 4. preoperative liver function assessment: child-pugh classification is a or b. 5. preoperative laboratory test: blood platlet count \> 100×10\^9/l, prothrombin activity \> 60%. 6. liver cirrhosis. exclusion criteria: 1. contraindication for surgery,e.g.severe disorders of circulation, respiratory or renal system. 2. extrahepatic metastasis in patients with malignancy or tumor invasion of portal vein, hepatic vein, bile duct or inferior vena cava. 3. hepatectomy accompanied with other organs resection(e.g. bile duct, intestine, pancreas or stomach) 4. regular hepatectomy. 5. tumors located in the left lateral lobe of liver. 6. previous hepatectomy. 7. pregnancy or lactation. 8. refusal to participate this trial.

Keywords: hepatocellular carcinoma blood loss haemorrhage vascular control
severe asthma network italy

Conditions: Severe Asthma

Summary: the goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time. the information recorded will provide: 1. the collection of homogeneous clinical, functional and biologic data of patients with severe asthma in a real life setting. 2. the evaluation of adherence to treatment in real life. 3. the clinical eligibility of patients treated with biologics. 4. the evaluation of patients' clinical response to each treatment. 5. the monitoring of tolerability and safety. 6. the long-term follow up of patients with severe asthma.


Eligibility criteria:
inclusion criteria: 1. signed informed consent and privacy disclaimer; 2. age \> 12 years; 3. diagnosis of severe asthma according to the ers/ats criteria: 1. during treatment with: * high-dose ics + at least one addistional controller (laba, montelukast, or theophylline) or * oral corticosteroids \>6 months/year 2. at least one of the following occurs or would occur if treatment would be reduced: * act \ 1.5 * at least 2 exacerbations in the last 12 months * at least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months * fev1 \<80% (if fev1/fvc below the lower limit of normal) exclusion criteria have not been considered in order to have a realistic view of severe asthma in real life.

Keywords: severe asthma network registry biologics adherence
neurofilament light chains and cognitive impairment in chronic psychiatric disease

Conditions: Schizophrenia; Bipolar Disorder; Alzheimer Disease; FTD

Summary: the validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. in a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in csf of psychiatric patients compared to neurodegenerative diseases. the main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. other biomarkers of interest (tau, tdp-43, gfap and uch-l1) will also be analyzed. a sub-part of this study will also focus on the retrospective analysis of the csf/plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.

one hundred twenty participants will be included in this study * 30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia) without cognitive impairment * 30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia) with cognitive impairment * 30 participants with a biological diagnosis of alzheimer's disease * 30 participants with frontotemporal dementia according to rascosky's criteria all the participants will perform cognitive, behavioral, and psychiatric evaluation and will be have blood sample taken.

Eligibility criteria:
inclusion criteria: * haven given written consent participants with psychiatric conditions: * schizophrenia (dsm-v criteria) with or without cognitive involution * bipolar disorder (dsm-v criteria) with or without cognitive involution participants with neurodegenerative disease: * probable or definite ftd (rascovsky criteria 2011) * biological alzheimer's disease with typical csf (nia-aa 2011) exclusion criteria: * uninterviewable patient and/or missing history * history of recent or previous head trauma with loss of consciousness * history of ischemic or hemorrhagic stroke * chronic alcoholism / chronic drug use * progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy * age \< 45 years * age \> 80 years * electroconvulsive therapy for less than 6 months

Keywords: dementia biomarker
masseter thickness, bruxism, and oral behaviors in chronic neck pain

Conditions: Neck Pain

Summary: a total of 30 patients aged 18-65 years who present with chronic non-specific neck pain and 30 healthy volunteers will be included in the study. patients with symptoms persisting for at least 3 months will be eligible for inclusion. necessary information will be provided to all participants, and informed consent will be obtained. to assess pain severity before treatment, participants will be asked to rate their complaints using the visual analog scale (vas), a linear scale for pain assessment. the neck disability index will be used to determine the level of disability. the jaw functional limitation scale-20 (jfls-20), patient health questionnaire-9 (phq-9), patient health questionnaire-15: physical symptoms, generalized anxiety disorder-7 (gad-7), and the oral behaviors checklist-included in axis 2 of the dc/tmd form developed for evaluating temporomandibular joint dysfunction-will be used to assess patients' psychosocial characteristics and parafunctional habits. additionally, masseter muscle thickness will be evaluated using ultrasonographic measurement.


Eligibility criteria:
inclusion criteria: * diagnosed with chronic non-specific neck pain * aged between 18-65 years * symptoms persisting for at least 3 months exclusion criteria: * pregnancy * presence of psychiatric or neurological diseases * use of psychiatric medications * cognitive impairment * history of neck injection or surgery within the last 6 months * presence of rheumatic diseases * spinal stenosis * cervical disc herniation * advanced degeneration detected in radiological imaging * history of fracture or surgery in the temporomandibular joint * presence of inflammatory, rheumatologic diseases, or malignancy affecting the t--emporomandibular joint
safety and performance of muscle activation for critical care patients

Conditions: Critically-ill

Summary: critically-ill patients who have long stays in the hospital often face prolonged periods of bed rest. it is known that these patient develop profound weakness and debilitation. the effectiveness of existing muscle activation devices that could otherwise prevent the onset of debilitation in an immobilized patient has not been demonstrated widely in this cohort. it is hypothesized that using thermal methods to augment existing muscle activation techniques may demonstrate improved performance with no corresponding change in the safety profile.


Eligibility criteria:
inclusion criteria: * patient is enrolled within 60 hours of admission to the icu * patient expected to be subject to bedrest in the icu for \> 96 hours exclusion criteria: * patient is age \< 18 years at time of consent * patient is pregnant * patient is moribund * patient has an implanted pacemaker/defibrillator * patient has a documented diagnosis of epilepsy * patient has implanted femoral rods * patient has leg or pelvic trauma that limits mobility * patient has recent trauma resulting in gcs \< 5 * patient lacks ability to walk without assistance prior to acute icu admission * patient has neuromuscular disease or abnormalities * patient is morbidly obese (bmi \> 40) * patient has a cognitive impairment or inability to follow commands prior to acute icu admission * patient was transferred after \> 48 hours at another acute care institution * enrollment in another investigational device or drug trial that could compromise the conduct or results of the study * evidence of disease or condition that, in the opinion of the physician, may compromise the conduct of or results of the study